Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix announces a c.$20.3m private placement

February 8, 2023
RNS Number : 2418P Renalytix PLC 08 February 2023   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES

Renalytix and Partners Awarded $10 Million Grant

January 26, 2023
RNS Number : 8999N Renalytix PLC 26 January 2023   Renalytix plc (" Renalytix " or the " Company ")     Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States   Award for consortium of industry,

Second Price Monitoring Extn

January 9, 2023
RNS Number : 1089M Renalytix PLC 09 January 2023   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

Price Monitoring Extension

January 9, 2023
RNS Number : 1075M Renalytix PLC 09 January 2023   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Completes Agreement with Veterans Administration

January 9, 2023
RNS Number : 0077M Renalytix PLC 09 January 2023   Renalytix plc (" Renalytix " or the " Company ")     Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems   Significant milestone will make KidneyIntelX accessible

Result of AGM

December 19, 2022
The 'Result of AGM' announcement released on 19/12/2022 at 12.01 under RNS No 1882K, did not include Resolutions 11 and 12. All Resolutions are now shown below and all other text remains the same.

Clinical utility study data: further highlights

December 1, 2022
RNS Number : 1709I Renalytix PLC 01 December 2022     Renalytix plc ("Renalytix" or the "Company")   Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes   First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to

Results for First Quarter of Fiscal Year 2023

November 30, 2022
RNS Number : 0037I Renalytix PLC 30 November 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023   LONDON and SALT LAKE CITY , November 30, 2022   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial

Publication of new real world evidence

November 29, 2022
RNS Number : 8468H Renalytix PLC 29 November 2022       Renalytix plc ("Renalytix" or the "Company")   Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease   Risk scoring by KidneyIntelX

Notice of Q1 FY23 Results

November 22, 2022
RNS Number : 1356H Renalytix PLC 22 November 2022       Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30   LONDON and SALT LAKE CITY , November 22, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that
Displaying 1 - 10 of 230